Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH).

OBJECTIVES Chronic hepatitis C virus (HCV) infection is associated with nonhepatocellular carcinoma malignancies. We aimed to evaluate whether achieving a sustained virological response (SVR, defined as HCV RNA seronegativity throughout posttreatment 24-week follow-up) could reduce the risk of non-hepatocellular carcinoma malignancy in a real-world nationwide Taiwanese Chronic Hepatitis C Cohort (T-COACH). METHODS A total of 10,714 patients with chronic hepatitis C who had received interferon-based therapy (8,186 SVR and 2,528 non-SVR) enrolled in T-COACH and were linked to the National Cancer Registry database for the development of 12 extrahepatic malignancies, including those with potential associations with HCV and with the top-ranking incidence in Taiwan, over a median follow-up period was 3.79 years (range, 0-16.44 years). RESULTS During the 44,354 person-years of follow-up, 324 (3.02%) patients developed extrahepatic malignancies, without a difference between patients with and without SVR (annual incidence: 0.69% vs 0.87%, respectively). Compared with patients with SVR, patients without SVR had a significantly higher risk of gastric cancer (0.10% vs 0.03% per person-year, P = 0.004) and non-Hodgkin lymphoma (NHL) (0.08% vs 0.03% per person-year, respectively, P = 0.03). When considering death as a competing risk, non-SVR was independently associated with gastric cancer (hazard ratio [HR]/95% confidence intervals [CIs]: 3.29/1.37-7.93, P = 0.008). When patients were stratified by age, the effect of SVR in reducing gastric cancer (HR/CI: 0.30/0.11-0.83) and NHL (HR/CI: 0.28/0.09-0.85) was noted only in patients aged <65 years but not those aged >65 years. DISCUSSION HCV eradication reduced the risk of gastric cancer and NHL, in particular among younger patients, indicating that patients with chronic hepatitis C should be treated as early as possible.

[1]  Ming-Ling Chang,et al.  The irreversible HCV-associated risk of gastric cancer following interferon-based therapy: a joint study of hospital-based cases and nationwide population-based cohorts , 2019, Therapeutic advances in gastroenterology.

[2]  H. El‐Serag,et al.  The effects of sustained virological response to direct‐acting anti‐viral therapy on the risk of extrahepatic manifestations of hepatitis C infection , 2019, Alimentary pharmacology & therapeutics.

[3]  M. Stepanova,et al.  Systematic review with meta‐analysis: extrahepatic manifestations in chronic hepatitis C virus‐infected patients in East Asia , 2019, Alimentary pharmacology & therapeutics.

[4]  M. Freiberg,et al.  Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events. , 2019, Gastroenterology.

[5]  Wen-Chung Lee,et al.  Taiwan's Nationwide Cancer Registry System of 40 years: Past, present, and future. , 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.

[6]  Ding‐Shinn Chen,et al.  Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection , 2018, Alimentary pharmacology & therapeutics.

[7]  F. Negro.  Expanded benefits of curing the extrahepatic manifestations of HCV infection , 2018, Gut.

[8]  P. Cacoub,et al.  Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis , 2018, Gut.

[9]  A. Chokkalingam,et al.  Risk of total non-hepatic cancer following treatment for HCV infection with direct-acting antiviral agents , 2018 .

[10]  S. Pol,et al.  Extrahepatic cancers and chronic HCV infection , 2018, Nature Reviews Gastroenterology & Hepatology.

[11]  A. Federico,et al.  Efficacy and safety of new direct antiviral agents in hepatitis C virus–infected patients with diffuse large B‐cell non‐Hodgkin's lymphoma , 2018, Hepatology.

[12]  J. Kramer,et al.  The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection , 2017, Gut.

[13]  E. Lebovics,et al.  Hepatitis C Virus and Nonliver Solid Cancers: Is There an Association between HCV and Cancers of the Pancreas, Thyroid, Kidney, Oral Cavity, Breast, Lung, and Gastrointestinal Tract? , 2017, Gastroenterology research and practice.

[14]  J. Sundquist,et al.  Cancer risk in patients with hepatitis C virus infection: a population‐based study in Sweden , 2017, Cancer medicine.

[15]  R. Bruno,et al.  Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. , 2016, Blood.

[16]  Ming‐Lung Yu,et al.  Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment , 2016, Clinical Cancer Research.

[17]  R. Hunt,et al.  Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report , 2016, Gut.

[18]  M. Yeh,et al.  The performance of acoustic radiation force impulse imaging in predicting liver fibrosis in chronic liver diseases , 2016, The Kaohsiung journal of medical sciences.

[19]  Ding‐Shinn Chen,et al.  Hepatitis C viral infection increases the risk of lymphoid‐neoplasms: A population‐based cohort study , 2016, Hepatology.

[20]  R. Gish,et al.  Hepatitis C virus as a systemic disease: reaching beyond the liver , 2015, Hepatology International.

[21]  T. Tseng,et al.  Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients. , 2015, Journal of the Formosan Medical Association = Taiwan yi zhi.

[22]  M. Yeh,et al.  Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. , 2014, Journal of hepatology.

[23]  M. Carrozzo,et al.  Oral manifestations of hepatitis C virus infection. , 2014, World journal of gastroenterology.

[24]  Chien-Jen Chen,et al.  Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. , 2012, The Journal of infectious diseases.

[25]  M Paulli,et al.  Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection , 2012, Leukemia.

[26]  F. Sung,et al.  Association between chronic viral hepatitis infection and breast cancer risk: a nationwide population-based case-control study , 2011, BMC Cancer.

[27]  Ming‐Lung Yu,et al.  Pegylated interferon plus ribavirin therapy improves pancreatic β‐cell function in chronic hepatitis C patients , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[28]  W. Briggs,et al.  Correlation of hepatitis C and prostate cancer, inverse correlation of basal cell hyperplasia or prostatitis and epidemic syphilis of unknown duration. , 2011, International braz j urol : official journal of the Brazilian Society of Urology.

[29]  Ming‐Lung Yu,et al.  Role of interleukin‐28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients , 2011, Hepatology.

[30]  N. Abraham,et al.  Identification of Helicobacter pylori infected patients, using administrative data , 2008, Alimentary pharmacology & therapeutics.

[31]  Shang-Jyh Hwang,et al.  Reappraisal of the Characteristics of Glucose Abnormalities in Patients With Chronic Hepatitis C Infection , 2008, The American Journal of Gastroenterology.

[32]  V. de Lédinghen,et al.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. , 2005, Gastroenterology.

[33]  A. Tursi,et al.  Detection of HCV RNA in gastric mucosa—associated lymphoid tissue by in situ hybridization: evidence of a new extrahepatic localization of HCV with increased risk of gastric malt lymphoma , 2002, American Journal of Gastroenterology.

[34]  D. Sansonno,et al.  Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: Viral detection in gastric low‐grade lymphoma associated with autoimmune disease and in chronic gastritis , 2000, Hepatology.

[35]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[36]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[37]  Y. Nagao,et al.  High prevalence of hepatitis C virus antibody and RNA in patients with oral cancer. , 1995, Journal of Oral Pathology & Medicine.

[38]  P. Scheuer,et al.  Classification of chronic viral hepatitis: a need for reassessment. , 1991, Journal of hepatology.

[39]  A. Antonelli,et al.  Thyroid involvement in hepatitis C — Associated mixed cryoglobulinemia , 2014, Hormones.

[40]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .